

# Sample Reports Booklet

The Harmony<sup>®</sup> prenatal test is a non-invasive prenatal test (NIPT) that evaluates the probability of trisomies (trisomy 21, 18 and 13) and additional menu options, including sex chromosome aneuploidies and 22q11.2 microdeletion by analyzing cell-free DNA (cfDNA) in maternal blood. This booklet provides sample reports for the Harmony prenatal test.

# TABLE OF CONTENTS

## Harmony Prenatal Test (Trisomy 21, Trisomy 18, Trisomy 13)

Low probability 1

Trisomy 21, high probability 2

## Fetal Sex Option

Fetal Sex, twin pregnancy, low probability 3

## Monosomy X Option

Monosomy X, high probability 4

## Sex Chromosome Aneuploidy (SCAP) Option

SCAP, low probability 5

SCAP low probability, Fetal Sex 6

SCAP high probability of Monosomy X, Fetal Sex 7

## 22q11.2 Option

22q11.2, no evidence of deletion 8

22q11.2, high probability 9

## Redraw Request

Redraw Request Report 10

# Trisomy 21, Trisomy 18, Trisomy 13 Low Probability



## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

PATIENT NAME: Jane Doe  
DATE OF BIRTH: (MM/DD/YYYY) 01/01/1980  
MRN: 1234567890123456789  
LABORATORY ID: AD12345678-PAT OTHER ID:  
GESTATIONAL AGE: 10 wks 5 days  
# OF FETUSES: 1 IVF STATUS: non-IVF pregnancy  
COLLECTION DATE (MM/DD/YYYY): 07/20/2015 RECEIVED DATE (MM/DD/YYYY): 07/21/2015

ACCOUNT #: 7654321  
CLINIC NAME: The Clinic Offering Test  
REFERRING/ORDERING CLINICIAN: Ordering Physician MD  
REFERRING/ORDERING CLINICIAN FAX #: 123-456-7890  
OTHER CLINICIAN: Genetic Counselor MA, CGC  
OTHER CLINICIAN FAX #: 987-654-3210  
REPORT DATE: (MM/DD/YYYY) 07/28/2015

### Questions:

sjc.clientservices@roche.com

US: (855) 927-4627

Intl: +1 (925) 854-6246

## Test Results

Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

### TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

### CLINICAL DATA

	Detection Rate	False Positive Rate
T21	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
T18	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
T13	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploid twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213

# Trisomy 21 High Probability



PRENATAL TEST  
www.harmonytest.com

## HIGH PROBABILITY RESULT

### Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (MM/DD/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID: AD12345678-PAT	OTHER ID:	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN:	Genetic Counselor MA, CGC
# OF FETUSES: 1	IVF STATUS: non-IVF pregnancy	OTHER CLINICIAN FAX #:	987-654-3210
COLLECTION DATE (MM/DD/YYYY) :	RECEIVED DATE (MM/DD/YYYY) :	REPORT DATE: (MM/DD/YYYY)	07/28/2015
07/20/2015	07/21/2015		

### Test Results Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	High Probability	Greater than 99/100 (99%)	Genetic counseling and additional testing
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

#### TEST DESCRIPTION

The Harmony Prenatal Test<sup>®</sup> measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony<sup>®</sup> performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

#### CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213

# Twin Pregnancy, Low Probability



## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

PATIENT NAME: Jane Doe

DATE OF BIRTH: (MM/DD/YYYY) 01/01/1980

MRN: 1234567890123456789

LABORATORY ID: AD12345678-PAT OTHER ID: \_\_\_\_\_

GESTATIONAL AGE: 10 wks 5 days

# OF FETUSES: 2 IVF STATUS: non-IVF pregnancy

COLLECTION DATE (MM/DD/YYYY): 07/20/2015 RECEIVED DATE (MM/DD/YYYY): 07/21/2015

ACCOUNT #: 7654321

CLINIC NAME: The Clinic Offering Test

REFERRING/ORDERING CLINICIAN: Ordering Physician MD

REFERRING/ORDERING CLINICIAN FAX #: 123-456-7890

OTHER CLINICIAN: Genetic Counselor MA, CGC

OTHER CLINICIAN FAX #: 987-654-3210

REPORT DATE: (MM/DD/YYYY) 07/28/2015

Questions:  
sjc.clientservices@roche.com

US: (855) 927-4627  
Intl: +1 (925) 854-6246

## Test Results Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

**Fetal Sex** **Male**

**TEST DESCRIPTION**

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

Fetal Sex test quantifies the Y chromosome. A "female" result indicates absence of Y chromosome and a "male" result indicates presence of Y chromosome. It does not exclude sex chromosome aneuploidy. For twin pregnancies, a male result indicates one or two male fetuses.

**CLINICAL DATA**

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**Fetal Sex:** > 99% accuracy for male or female sex (95% CI: 99.2-100%)

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

# Monosomy X, High Probability



**harmony**  
 PRENATAL TEST  
[www.harmonytest.com](http://www.harmonytest.com)

### Patient and Provider Information

Ariosa Diagnostics, Inc.  
 5945 Optical Court  
 San Jose, CA 95138

PATIENT NAME: **Jane Doe**  
 DATE OF BIRTH: **01/01/1980**  
 MRN: **1234567890123456789**  
 LABORATORY ID: **AD12345678-PAT** OTHER ID:  
 GESTATIONAL AGE: **10 wks 5 days**  
 # OF FETUSES: **1** IVF STATUS: **non-IVF pregnancy**  
 COLLECTION DATE (MM/DD/YYYY) : **07/20/2015** RECEIVED DATE (MM/DD/YYYY) : **07/21/2015**

ACCOUNT #: **7654321**  
 CLINIC NAME: **The Clinic Offering Test**  
 REFERRING/ORDERING CLINICIAN: **Ordering Physician MD**  
 REFERRING/ORDERING CLINICIAN FAX #: **123-456-7890**  
 OTHER CLINICIAN: **Genetic Counselor MA, CGC**  
 OTHER CLINICIAN FAX #: **987-654-3210**  
 REPORT DATE: **07/28/2015**

**Questions:**

[sjc.clientservices@roche.com](mailto:sjc.clientservices@roche.com)

US: (855) 927-4627

Intl: +1 (925) 854-6246

### Test Results

Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

### Monosomy X

**Monosomy X greater than 99% probability - Recommend genetic counseling**

#### TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

Monosomy X test quantifies the X chromosome. Monosomy X is reported at a probability of 1% or greater. It does not exclude other sex chromosome aneuploidies. Monosomy X has only been validated in singleton pregnancies.

#### CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**Monosomy X:** Monosomy X provides probability for non-mosaic Monosomy X. Limited numbers of Monosomy X cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213

# SCAP, Low Probability



## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

PATIENT NAME: **Jane Doe**  
 DATE OF BIRTH: **01/01/1980**  
 MRN: **1234567890123456789**  
 LABORATORY ID: **AD12345678-PAT** OTHER ID:  
 GESTATIONAL AGE: **10 wks 5 days**  
 # OF FETUSES: **1** IVF STATUS: **non-IVF pregnancy**  
 COLLECTION DATE (MM/DD/YYYY): **07/20/2015** RECEIVED DATE (MM/DD/YYYY): **07/21/2015**

ACCOUNT #: **7654321**  
 CLINIC NAME: **The Clinic Offering Test**  
 REFERRING/ORDERING CLINICIAN: **Ordering Physician MD**  
 REFERRING/ORDERING CLINICIAN FAX #: **123-456-7890**  
 OTHER CLINICIAN: **Genetic Counselor MA, CGC**  
 OTHER CLINICIAN FAX #: **987-654-3210**  
 REPORT DATE: **07/28/2015**

**Questions:**

sjc.clientservices@roche.com

US: (855) 927-4627

Intl: +1 (925) 854-6246

## Test Results

Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

<b>Fetal Sex</b>	<b>Female</b>
<b>Sex Chromosome Aneuploidy Panel</b>	<b>Low Probability</b>

### TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

Fetal Sex test quantifies the Y chromosome. A "female" result indicates absence of Y chromosome and a "male" result indicates presence of Y chromosome. It does not exclude sex chromosome aneuploidy. For twin pregnancies, a male result indicates one or two male fetuses.

Sex Chromosome Aneuploidy (SCA) Panel measures proportions of the X and Y chromosomes. Sex chromosome conditions (Monosomy X, XXY, XYY, XXX, XXYY) are reported at probabilities of 1% or greater. An XYY or XXYY result indicates two or more fetal Y chromosomes. Sex Chromosome Aneuploidy Panel has only been validated in singleton pregnancies.

### CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**Fetal Sex:** > 99% accuracy for male or female sex (95% CI: 99.2-100%)

**SCA Panel:** SCA Panel provides probability for non-mosaic fetal sex chromosome aneuploidies. Test performance varies by condition. Limited numbers of sex chromosome aneuploidy cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213

## SCAP, Low Probability, Fetal Sex



**harmony**

PRENATAL TEST  
www.harmonytest.com

## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

## Questions:

sjc.clientservices@roche.com

US: (855) 927-4627

Intl: +1 (925) 854-6246

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (MM/DD/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID: AD12345678-PAT	OTHER ID:	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN:	Genetic Counselor MA, CGC
# OF FETUSES: 1	IVF STATUS: non-IVF pregnancy	OTHER CLINICIAN FAX #:	987-654-3210
COLLECTION DATE (MM/DD/YYYY): 07/20/2015	RECEIVED DATE (MM/DD/YYYY): 07/21/2015	REPORT DATE: (MM/DD/YYYY)	07/28/2015

## Test Results

Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

## Fetal Sex

Female

## Sex Chromosome Aneuploidy Panel

Low Probability

## TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

Fetal Sex test quantifies the Y chromosome. A "female" result indicates absence of Y chromosome and a "male" result indicates presence of Y chromosome. It does not exclude sex chromosome aneuploidy. For twin pregnancies, a male result indicates one or two male fetuses.

Sex Chromosome Aneuploidy (SCA) Panel measures proportions of the X and Y chromosomes. Sex chromosome conditions (Monosomy X, XXY, XYY, XXX, XYYY) are reported at probabilities of 1% or greater. An XYY or XYYY result indicates two or more fetal Y chromosomes. Sex Chromosome Aneuploidy Panel has only been validated in singleton pregnancies.

## CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploid twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**Fetal Sex:** > 99% accuracy for male or female sex (95% CI: 99.2-100%)

**SCA Panel:** SCA Panel provides probability for non-mosaic fetal sex chromosome aneuploidies. Test performance varies by condition. Limited numbers of sex chromosome aneuploidy cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213



# SCAP, High Probability of Monosomy X, Fetal Sex



## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

**Questions:**

sjc.clientservices@roche.com

US: (855) 927-4627

Intl: +1 (925) 854-6246

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (MM/DD/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID: OTHER ID:	AD12345678-PAT	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN:	Genetic Counselor MA, CGC
# OF FETUSES: IVF STATUS:	1 non-IVF pregnancy	OTHER CLINICIAN FAX #:	987-654-3210
COLLECTION DATE (MM/DD/YYYY): RECEIVED DATE (MM/DD/YYYY):	07/20/2015 07/21/2015	REPORT DATE: (MM/DD/YYYY)	07/28/2015

## Test Results Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

<b>Fetal Sex</b>	<b>Female</b>
<b>Sex Chromosome Aneuploidy Panel</b>	<b>Monosomy X greater than 99% probability - Recommend genetic counseling</b>

**TEST DESCRIPTION**

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

Fetal Sex test quantifies the Y chromosome. A "female" result indicates absence of Y chromosome and a "male" result indicates presence of Y chromosome. It does not exclude sex chromosome aneuploidy. For twin pregnancies, a male result indicates one or two male fetuses.

Sex Chromosome Aneuploidy (SCA) Panel measures proportions of the X and Y chromosomes. Sex chromosome conditions (Monosomy X, XXY, XYY, XXX, XYY) are reported at probabilities of 1% or greater. An XYY or XYY result indicates two or more fetal Y chromosomes. Sex Chromosome Aneuploidy Panel has only been validated in singleton pregnancies.

**CLINICAL DATA**

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**Fetal Sex:** > 99% accuracy for male or female sex (95% CI: 99.2-100%)

**SCA Panel:** SCA Panel provides probability for non-mosaic fetal sex chromosome aneuploidies. Test performance varies by condition. Limited numbers of sex chromosome aneuploidy cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

## 22q11.2, No Evidence of Deletion



**harmony**

PRENATAL TEST  
www.harmonytest.com

## Patient and Provider Information

Ariosa Diagnostics, Inc.  
5945 Optical Court  
San Jose, CA 95138

## Questions:

sjc.clientservices@roche.com

US: (855) 927-4627

Intl: +1 (925) 854-6246

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (MM/DD/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID:	AD12345678-PAT	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN:	Genetic Counselor MA, CGC
# OF FETUSES:	1	OTHER CLINICIAN FAX #:	987-654-3210
IVF STATUS:	non-IVF pregnancy	REPORT DATE: (MM/DD/YYYY)	07/28/2015
COLLECTION DATE (MM/DD/YYYY):	07/20/2015	RECEIVED DATE (MM/DD/YYYY):	07/21/2015

## Test Results

Fetal cfDNA Percentage: 10.5%

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

## 22q11.2

No evidence of a deletion observed

## TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

22q11.2 test uses targeted analysis of chromosome cfDNA fragments from within a 3Mb region of 22q11.21 to determine the probability of a deletion. "High probability of a deletion" indicates that the analysis detected a decrease of cfDNA fragments consistent with a deletion in the 22q11.21 region, which may be fetal, maternal or both. "No evidence of a deletion observed" indicates the analysis does not find an increased probability for a deletion in the 22q11.21 region. Not all fetuses with 22q11.2 deletions will be classified as high probability. This test does not rule out the possibility of other clinically significant aneuploidy, single gene conditions, microdeletions or microduplications being present in the fetus. Women with a known 22q11.2 deletion are not eligible for this test. 22q11.2 test has only been validated in singleton pregnancies.

## CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**22q11.2:** Limited numbers of 22q11.2 cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

MC-US-02213

# 22q11.2, High Probability



**harmony**  
 PRENATAL TEST  
[www.harmonytest.com](http://www.harmonytest.com)

## Patient and Provider Information

Ariosa Diagnostics, Inc.  
 5945 Optical Court  
 San Jose, CA 95138

**Questions:**

[sjc.clientservices@roche.com](mailto:sjc.clientservices@roche.com)

US: (855) 927-4627

Intl: +1 (925) 854-6246

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (MM/DD/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID:	AD12345678-PAT	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
OTHER ID:		OTHER CLINICIAN:	Genetic Counselor MA, CGC
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN FAX #:	987-654-3210
# OF FETUSES:	1	REPORT DATE: (MM/DD/YYYY)	07/28/2015
IVF STATUS:	non-IVF pregnancy		
COLLECTION DATE (MM/DD/YYYY):	07/20/2015	RECEIVED DATE (MM/DD/YYYY):	07/21/2015

Test Results			Fetal cfDNA Percentage: 10.5%
CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 18 (T18)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Probability	Less than 1/10,000 (0.01%)	Review results with patient

### 22q11.2

High probability of a deletion - Recommend genetic counseling

#### TEST DESCRIPTION

The Harmony Prenatal Test® measures the relative proportion of chromosomes to aid in the assessment of fetal trisomies 21, 18, and 13. Harmony® performs a directed analysis of cell-free DNA (cfDNA) in maternal blood and incorporates the fetal fraction of cfDNA in test results. Test results also incorporate maternal age (or egg donor age) and gestational age related probability based on information provided on the test requisition form. Probability of less than 1% is defined as low probability and 1% or greater is defined as high probability. Harmony has been validated in singleton and twin pregnancies of at least 10 weeks gestational age. Harmony is not validated for use in pregnancies with more than two fetuses, demised twin, mosaicism, partial chromosome aneuploidy, translocations, maternal aneuploidy, transplant, malignancy, or in women under the age of 18. Harmony does not detect neural tube defects. Twin results reflect the probability that the pregnancy involves at least one affected fetus. Analysis of cfDNA does not always correlate with fetal genotype. Not all aneuploid fetuses will have a high probability result and some euploid fetuses will have a high probability result. The Harmony Prenatal Test is not a diagnostic test and results should be considered with other clinical criteria and communicated in a setting that includes appropriate counseling.

22q11.2 test uses targeted analysis of chromosome cfDNA fragments from within a 3Mb region of 22q11.21 to determine the probability of a deletion. "High probability of a deletion" indicates that the analysis detected a decrease of cfDNA fragments consistent with a deletion in the 22q11.21 region, which may be fetal, maternal or both. "No evidence of a deletion observed" indicates the analysis does not find an increased probability for a deletion in the 22q11.21 region. Not all fetuses with 22q11.2 deletions will be classified as high probability. This test does not rule out the possibility of other clinically significant aneuploidy, single gene conditions, microdeletions or microduplications being present in the fetus. Women with a known 22q11.2 deletion are not eligible for this test. 22q11.2 test has only been validated in singleton pregnancies.

#### CLINICAL DATA

	Detection Rate	False Positive Rate
<b>T21</b>	> 99% (95% CI: 97.9-99.8%)	< 0.1% (95% CI: 0.02-0.08%)
<b>T18</b>	97.4% (95% CI: 93.4-99.0%)	< 0.1% (95% CI: 0.01-0.05%)
<b>T13</b>	93.8% (95% CI: 79.9-98.3%)	< 0.1% (95% CI: 0.01-0.06%)

Detection and false positive (discordant result) rates based on probability cut-off of 1/100 (1%). Because these conditions are rare, limited numbers of aneuploidy twin and egg donor pregnancies have been evaluated. The negative predictive value for trisomy 21, 18, and 13 is greater than 99%. Positive predictive value (PPV) varies by prevalence. The probability result reported is not equivalent to the PPV. For more information regarding PPV refer to: <http://www.harmonytest.com/PPV>

**22q11.2:** Limited numbers of 22q11.2 cases have been evaluated to date.

REFERENCES: Stokowski R et al. Prenatal Diagnosis 2015; 35, 1-4; Data on file.

The Harmony Prenatal Test was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory in San Jose, CA USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. This testing service has not been cleared or approved by the US FDA. Harmony is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis and is considered a prenatal screening test, not a diagnostic test. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.

HARMONY and HARMONY PRENATAL TEST and design are trademarks of Ariosa Diagnostics, Inc. in the US. HARMONY is a trademark of Roche in other countries. All other trademarks are the property of their respective owners.

# Harmony Redraw Report




## Patient and Provider Information

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH: (DD/MM/YYYY)	01/01/1980	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
LABORATORY ID:	OTHER ID:	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
AD12345678-PAT		OTHER CLINICIAN:	Genetic Counselor MA, CGC
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN FAX #:	987-654-3210
# OF FETUSES:	1	IVF STATUS:	non-IVF pregnancy
COLLECTION DATE (DD/MM/YYYY):	20/07/2015	RECEIVED DATE (DD/MM/YYYY):	21/07/2015
		REPORT DATE: (DD/MM/YYYY)	28/07/2015

## Specimen Redraw Request

**Reliable NIPT evaluation on this sample was not possible for the following reason(s):**

- Time between blood draw date and receipt of sample exceeded laboratory processing requirements
- Blood collection tubes were missing from the shipment
- Incorrect blood collection tube(s) used
- Expired blood collection tube(s) used
- Specimen quantity not sufficient
- Specimen hemolysis observed
- Blood collection tubes damaged during shipping/accessioning
- The blood collection tube barcodes did not match the test requisition barcode
- Patient Name and/or Patient DOB on blood collection tube label(s) did not match the test requisition form
- A result was not obtained due to insufficient fetal cfDNA for accurate NIPT evaluation
- A result was not obtained because the sample did not meet thresholds for quality control
- A result was not obtained because of laboratory processing or specimen issues

*Reordering of the Harmony Prenatal Test is suggested. Consideration of whether to redraw a specimen should take into account other clinical criteria. If you have any questions about this notification, please contact Client Services via the contact information listed above.*

# Understanding NIPT results

What type of Harmony Prenatal test report was issued?	Why was that report issued?	What is clinically indicated next?
<b>Low-probability result</b>	<ul style="list-style-type: none"> <li>NIPT results indicate a low-probability result</li> <li>Most likely fetus is unaffected<sup>1</sup></li> <li>Very low chance of false negative<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>Review results with patient<sup>2</sup></li> <li>Continue standard prenatal care<sup>2</sup></li> </ul>
<b>High-probability result</b>	<ul style="list-style-type: none"> <li>NIPT result indicates a high-probability result for specified condition</li> <li>Explanations include the fetus may be affected, false positive, or maternal factors<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>Genetic counseling is recommended<sup>2</sup></li> <li>Consideration of additional testing options<sup>2</sup></li> <li>Call Client Services with questions: 1-855-927-4672</li> </ul>
<b>Specimen redraw request</b>	<ul style="list-style-type: none"> <li>Reliable NIPT analysis could not be performed<sup>3</sup></li> <li>Insufficient sample<sup>3</sup></li> <li>Problem with sample or blood collection tubes<sup>3</sup></li> <li>Low fetal fraction<sup>3,4</sup></li> <li>Laboratory processing or specimen issues<sup>3</sup></li> <li>Failure to meet thresholds for quality control<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>Take all clinical factors into account and consider obtaining another patient sample for testing<sup>5</sup></li> <li>Review the Redraw Request report to understand the reason the result could not be obtained.</li> <li>Call Client Services with questions: 1-855-927-4672</li> </ul>
<b>Test canceled</b>	<ul style="list-style-type: none"> <li>Patient doesn't meet requirements for testing (examples: gestational age less than 10 weeks, triplet gestation)<sup>3,6</sup></li> <li>Incomplete test requisition form (TRF) after several attempts to contact office</li> <li>Assay failure</li> </ul>	<ul style="list-style-type: none"> <li>Take all clinical and logistic factors into account and consider re-ordering the patient's Harmony test.<sup>2</sup></li> <li>Consider alternative prenatal screening or diagnostic testing.<sup>2</sup></li> <li>Call Client Services with questions: 1-855-927-4672</li> </ul>
<b>Low-probability trisomy 21, 18, and 13, but test is inconclusive for fetal sex and/or sex chromosome aneuploidy panel</b>	<ul style="list-style-type: none"> <li>Technical reasons may include variance in the assay data</li> <li>Biological reasons may include demised co-twin, mosaicism (placental, fetal, or maternal) or copy number variant</li> </ul>	<ul style="list-style-type: none"> <li>An inconclusive fetal sex and/or sex chromosome aneuploidy panel does not affect the accuracy of the trisomy screen.</li> <li>Repeat testing is not recommended (Repeat NIPT analysis would not be expected to yield a result)</li> <li>Consider alternative testing for fetal sex, such as ultrasound, and/or alternative testing for sex chromosome aneuploidies, such as diagnostic testing.</li> <li>Call Client Services with questions: 1-855-927-4672</li> </ul>

## COMMON REASONS FOR A SPECIMEN REDRAW REQUEST

### LOW FETAL FRACTION

Approximately three percent of samples will not obtain a result, and the most common cause is due to low fetal fraction. Low FF can happen for a variety of biological reasons, including maternal weight, gestational age, and other factors that aren't well understood: ethnicity, exercise, medications, etc. Fetal cfDNA increases with gestation, decreases with increasing maternal weight, and generally provides a successful result upon second blood draw when the first attempt had insufficient fetal cfDNA.<sup>4</sup>

Some studies have indicated that samples with a low fetal fraction may have some higher risk of aneuploidy.<sup>3,7</sup>

Measuring the fetal fraction is an essential quality metric that ACOG and ACMG recommend all NIPTs should perform.

### FAILURE TO MEET THRESHOLDS FOR QUALITY CONTROL

There are often technical reasons the test could not obtain a result. There may not be enough cfDNA in the sample or cfDNA of high enough quality. There may not be enough informative SNPs to accurately measure the fetal fraction in a given sample. Or there are biological factors, such as an undiagnosed vanishing twin, that can affect the results.

### SPECIMEN HANDLING

The reasons for a redraw request can include having an insufficient sample size, improperly labeled tubes, and incorrect notation of twins or egg donor.

References: 1. Stokowski et al. *Prenat Diagn.* 2015; 35: 1243-1246. 2. ACOG Committee Position 640. *Obstet Gynecol.* 2015 Sep;126(3):e31-7 3. Norton et al. *NEJM.* 2015 Apr; 372(17):1589-97 4. Wang et al. *Prenat Diagn.* 2013 Jul;33(7):662-6 5. Revello et al. *Ultrasound Obstet Gynecol.* 2016 Jun;47(6):698-704 6. Bevilacqua et al. *Ultrasound Obstet Gynecol* 2015; 45: 61-66 7. Pergament et al. *Obstet Gynecol* 2014; 124(2 Pt 1):210-8. 8. ACMG: Gregg et al. *Genet Med.* 2016 Jul 18. 9. Schmid M et al. *Ultrasound Obstet Gynecol.* 2018 Feb 26. doi:10.1111/1469-7580.1386

**For assistance email [sjc.clientservices@roche.com](mailto:sjc.clientservices@roche.com)  
or call 1-855-927-4672**

The Harmony Prenatal Test was developed by Ariosa Diagnostics, a CLIA-certified laboratory. As with other lab-developed tests, it has not been cleared or approved by the FDA and is not available for sales as an IVD in the U.S. Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing.

ARIOSA, the Ariosa Logo, ARIOSA DIAGNOSTICS, the Ariosa Diagnostics Logo, HARMONY PRENATAL TEST and HARMONY are trademarks of Roche. All other trademarks are the property of their respective owners.  
©2018 Roche MC-US-02213-1118

Roche Diagnostics  
9115 Hague Road  
Indianapolis, IN 48258

MC-US-02213

Signature Page for MC-US-02213 v1.0

Medical Approval	Ashley Allen Medical 03-Dec-2018 17:17:37 GMT+0000
------------------	--

Regulatory Approval	Beth Wolf Regulatory 04-Dec-2018 16:03:55 GMT+0000
---------------------	--

Signature Page for MC-US-02213 v1.0